The global microbiome sequencing services market size reached USD 2,610.6 Million in 2024 and is expected to reach USD 11,260.5 Million by 2033, growing at a CAGR of 16.75% during 2025-2033. This market growth is driven by increasing incidences of infectious diseases, rising preference for microbiome-based therapeutics including fecal microbiota transplantation (FMT), and expanding use of microbiome sequencing in veterinary medicine. The Microbiome Sequencing Services Market offers valuable insights into technological advancements and application trends.
Study Assumption Years
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Period: 2025-2033
Microbiome Sequencing Services Market Key Takeaways
- The global market size was valued at USD 2,610.6 Million in 2024, with an expected CAGR of 16.75% during 2025-2033.
- Increasing infectious disease incidences are driving demand for microbiome services to study host-pathogen interactions.
- Rising adoption of microbiome-based therapeutics such as FMT necessitates accurate microbiome profiling.
- Growing use in veterinary medicine supports animal health, disease prevention, and livestock production.
- North America currently dominates the market due to early diagnosis awareness and prevalence of colorectal cancer.
- The pharmaceutical industry expansion fuels microbiome data application in novel drug development targeting gastrointestinal diseases.
Sample Request Link: https://www.imarcgroup.com/microbiome-sequencing-services-market/requestsample
Market Growth Factors
The global microbiome sequencing services market is propelled by increasing incidences of infectious diseases worldwide, which catalyze demand for detailed analysis of host-pathogen relationships. Microbiome sequencing enables researchers and healthcare professionals to understand microbial communities better, aiding in the development of diagnostics and therapies, thereby escalating market growth.
The rising inclination towards microbiome-based therapeutics, including fecal microbiota transplantation (FMT), drives the need for precise microbiome profiling to ensure treatment efficacy and safety. This therapeutic trend is boosting the adoption of microbiome sequencing services significantly, as these services are essential for monitoring and validating such treatments.
Moreover, expanding usage in veterinary medicine to improve animal health and livestock productivity influences market growth positively. The pharmaceutical industry's expansion supports leveraging microbiome data to develop drugs, especially for gastrointestinal diseases. Additionally, the rise of precision agriculture practices relying on microbiome data further sustains demand.
Market Segmentation
Breakup by Technology:
- Sequencing by Synthesis (SBS): Dominates the market as the core technology for microbiome sequencing; involves incorporating fluorescent nucleotides into DNA strands to decode microbial genetic material accurately.
- Sequencing by Ligation (SBL)
- Pyrosequencing
- Sanger Sequencing
- Others
Breakup by Research Type:
- Outsourced Research: Holds the largest market share by leveraging external partners with advanced capabilities to address complex microbiome analyses.
- Internal Research
Breakup by Laboratory Type:
- Wet Labs: Account for the largest share; perform sample preparation including DNA extraction and sequencing library preparation.
- Dry Labs
Breakup by Application:
- Shotgun Sequencing: Largest segment; sequences entire microbial DNA for a comprehensive view of microbial diversity without targeting specific genes.
- Targeted Gene Sequencing
- RNA Sequencing
- Whole Genome Sequencing
- Others
Breakup by End User:
- Pharmaceutical and Biotechnology Companies: Largest segment; utilize microbiome data for drug discovery, therapeutic development, and microbiome-based therapies.
- Research and Academic Institutes
- Others
Regional Insights
North America dominates the microbiome sequencing services market, driven by awareness of early diagnosis benefits and colorectal cancer prevalence. The growing geriatric population also positively impacts demand. Asia Pacific is expected to exhibit stable growth due to investments in novel drug development, extensive R&D activities, and integration of advanced technologies.
Recent Developments & News
In 2022, Diversigen Inc (OraSure Technologies Inc.) launched metatranscriptomic sequencing and analysis services targeting gut microbiome samples. This advancement enhances the capability to analyze microbial gene expression, enabling deeper insights into microbiome dynamics.
Key Players
- BaseClear B.V.
- Clinical-Microbiomics A/S
- Diversigen Inc (OraSure Technologies Inc.)
- Mrieux NutriSciences
- Metabiomics Corporation (BioSpherex LLC)
- Microbiome Insights Inc.
- Microbiome Therapeutics LLC
- Molecular Research LP
- Molzym GmbH & Co. KG
- Resphera Biosciences LLC
- Shanghai Realbio Technology (RBT) Co. Ltd.
- Zymo Research Corporation
Get Custom Market Research Report for Your Business:
https://www.imarcgroup.com/request?type=report&id=4357&flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
